CELU Long Call Strategy

CELU (Celularity Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements.

CELU (Celularity Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $14.9M, a beta of 0.48 versus the broader market, a 52-week range of 0.566-4.35, average daily share volume of 135K, a public-listing history dating back to 2019, approximately 120 full-time employees. These structural characteristics shape how CELU stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.48 indicates CELU has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on CELU?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current CELU snapshot

As of June 30, 2026, spot at $0.62, ATM IV 17.50%, IV rank 0.00%, expected move 5.02%. The long call on CELU below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long call structure on CELU specifically: CELU IV at 17.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a CELU long call, with a market-implied 1-standard-deviation move of approximately 5.02% (roughly $0.03 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CELU expiries trade a higher absolute premium for lower per-day decay. Position sizing on CELU should anchor to the underlying notional of $0.62 per share and to the trader's directional view on CELU stock.

CELU long call setup

The CELU long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CELU near $0.62, the first option leg uses a $0.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CELU chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CELU shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$0.62N/A

CELU long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

CELU long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on CELU. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on CELU

Long calls on CELU express a bullish thesis with defined risk; traders use them ahead of CELU catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

CELU thesis for this long call

The market-implied 1-standard-deviation range for CELU extends from approximately $0.59 on the downside to $0.65 on the upside. A CELU long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CELU IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CELU at 17.50%. As a Healthcare name, CELU options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CELU-specific events.

CELU long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CELU positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CELU alongside the broader basket even when CELU-specific fundamentals are unchanged. Long-premium structures like a long call on CELU are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CELU chain quotes before placing a trade.

Frequently asked questions

What is a long call on CELU?
A long call on CELU is the long call strategy applied to CELU (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CELU stock trading near $0.62, the strikes shown on this page are snapped to the nearest listed CELU chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CELU long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CELU long call priced from the end-of-day chain at a 30-day expiry (ATM IV 17.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CELU long call?
The breakeven for the CELU long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CELU market-implied 1-standard-deviation expected move is approximately 5.02%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on CELU?
Long calls on CELU express a bullish thesis with defined risk; traders use them ahead of CELU catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current CELU implied volatility affect this long call?
CELU ATM IV is at 17.50% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related CELU analysis